BeiGene stock surges on EU approval for TEVIMBRA in advanced cancer treatment

BeiGene, a global oncology company, announced that the European Commission has granted regulatory approval for TEVIMBRA (tislelizumab), its PD-1 monoclonal antibody, for the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. This approval marks a significant milestone in oncology, offering new hope for patients with limited survival prospects.

Shares of BeiGene rose sharply, climbing 8.2% to $207.80 following the announcement. The therapy, which combines with chemotherapy for its newly approved indications, has demonstrated substantial improvements in overall survival (OS) rates in pivotal clinical trials.

TEVIMBRA: A game-changing cancer therapy

TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody designed to enhance immune responses against tumors while reducing unnecessary interactions with other immune receptors. This unique mechanism of action enables TEVIMBRA to help the body’s immune system detect and attack cancer more effectively.

The therapy’s expanded indication approval is based on compelling results from BeiGene’s global Phase 3 RATIONALE clinical trials. The RATIONALE-306 study for ESCC enrolled 649 patients across three continents, demonstrating a 34% reduction in the risk of death for patients treated with TEVIMBRA and chemotherapy. In the trial, median OS improved to 17.2 months from 10.6 months for the placebo group.

Similarly, the RATIONALE-305 trial for G/GEJ cancer included 997 patients and showed a 20% reduction in mortality risk. Patients treated with TEVIMBRA in combination with chemotherapy experienced a median OS of 15.0 months compared to 12.9 months in the control group.

Expert insights emphasize urgency for advanced cancer therapies

Florian Lordick, Director of the University Cancer Center Leipzig, noted that patients with advanced gastric and esophageal cancers often face survival times measured in months. He highlighted the potential of TEVIMBRA to transform outcomes for these patients, emphasizing the statistically significant benefits observed in clinical trials.

TEVIMBRA is now approved in 42 countries and has been used to treat over 1.3 million patients worldwide. It also forms the backbone of BeiGene’s solid tumor treatment portfolio, demonstrating versatility across multiple cancer types.

Safety data and next steps

The safety profile of TEVIMBRA was evaluated across more than 2,800 patients in clinical trials, with most adverse reactions, such as neutropenia and fatigue, being manageable. This rigorous safety analysis supports BeiGene’s commitment to delivering effective treatments while ensuring patient safety.

With this latest approval, BeiGene solidifies its presence in the European oncology market, building on its momentum from securing EU authorisation for six indications in just over a year. Mark Lanasa, BeiGene’s Chief Medical Officer for Solid Tumors, stated that the company aims to ensure broad and rapid access to TEVIMBRA for eligible patients across Europe.

In alignment with its mission to eliminate cancer, BeiGene recently announced plans to rebrand as BeOne Medicines Ltd., reinforcing its dedication to collaboration and innovation in oncology.